The 0.375% convertible senior notes are due 2028

Davis Polk advised the representatives of the several initial purchasers in connection with a Rule 144A offering by DexCom, Inc. of $1.25 billion aggregate principal amount of its 0.375% convertible senior notes due 2028, which included $150 million aggregate principal amount of notes issued pursuant to the exercise in full of the initial purchasers’ option to purchase additional notes. In addition, Davis Polk advised the counterparties to capped call transactions entered into in connection with the offering.

Headquartered in San Diego, California, DexCom, Inc. is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring systems for use by people with diabetes and by healthcare providers.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Joseph G. Marano and Dove Barbanel. The equity derivatives team included partner Mark J. DiFiore, counsel Faisal Baloch and associates Danielle Forni and Eugenia S. Lee. The tax team included partner Michael Farber and associate Justin Corvino.  Partner Pritesh P. Shah provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.